MAPT and Alzheimer disease: Also similar to human AD [27–29], the PS19 mice exhibited elevated brain tau, thinning of the hippocampal neuronal cell layers, decreased mossy fiber synaptophysin staining, and elevated glial activation, all of which were improved with PDDC.